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ABSTRACT 
In pre-clinical models the only two chemotherapy drugs which have been demonstrated 
to directly reduce the number of myeloid derived suppressor cells (MDSCs) are 
gemcitabine and 5-fluorouracil (5-FU). Here we analyse the dynamics of MDSCs, 
phenotyped as Lin-DR-CD11b+, in patients with advanced pancreatic cancer receiving 
the combination of gemcitabine and capecitabine, a 5-FU pro-drug. Gemcitabine and 
capecitabine reduced MDSCs in 58% of patients (n = 19). MDSC% fell in 3/9 patients 
with above-median baseline MDSCs, conversely in 5/8 patients with minimal tumour 
volume change on treatment the MDSC% went up. Increases in MDSC% in patients with 
unchanged tumour volume appeared to correlate with sustained cancer-related 
inflammatory cytokine up-regulation. Thus, we found no evidence that gemcitabine and 
capecitabine directly reduces MDSC% in patients: increased tumour burden or sustained 
cancer-related inflammation during chemotherapy are likely to be associated with 
increased MDSC levels. In a separate cohort of 21 patients treated with gemcitabine and 
capecitabine together with a concurrently administered telomerase vaccine, the MDSC 
level fell in 8 of the 9 patients who developed an immune response to the vaccine. 6 of 
these patients had above-median pre-vaccination MDSC levels. Thus, a high pre-
vaccination MDSC% does not preclude development of immunity to a tumour-associated 
antigen. This data suggests that antigen-immunity is more likely to develop when a 
cancer vaccine is administered in the context of adjunctive treatment which actively 
checks the progress of increasing immunosuppression which occurs with increasing 
disease volume and/or sustained levels of cancer-related inflammation. 
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This paper demonstrates no evidence that Gemcitabine and Capecitabine directly reduce 
MDSC% in patients. Any decrease in MDSC levels is likely to reflect predominantly the 
effect of the resultant disease control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
MDSCs are a heterogeneous family of immature myeloid cells arrested in their 
differentiation program by a variety of tumor-secreted factors. MDSCs inhibit the activity 
of CTLs in a variety of ways: high levels of intracellular arginase in MDSCs depletes the 
cellular micro-environment of arginine, an essential amino acid for T-cell activation [1]; 
uptake and depletion of cystine by MDSCs depletes T cells of a further amino acid 
required for T-cell activation [2]; MDSC-mediated down-regulation of L- selectin, a 
molecule that targets T-cells to lymph nodes [3]; the production by MDSCs of the free 
radical peroxynitrite, which causes the nitration/nitrosylation of the T-cell receptors and 
CD8 molecules of CTLs, thus preventing their recognition of the peptide-MHC complex 
on tumour cells [4]. This latter suppressive mechanism has been recently described to 
operate at the level of the cancer cell where MDSC production of peroxynitrite causes 
tyrosine nitrosylation of the MHC class I molecules on tumor cells thus preventing the 
binding of peptide epitopes [5]. 
Chemotherapy remains the standard treatment for inoperable pancreatic cancer, and 
various data suggest that two of the main chemotherapeutic agents used in this disease 
may impact beneficially on MDSCs. In a pivotal paper, mice harboring a variety of 
different tumors were treated with a single dose of Gemcitabine and the impact on the 
percentage of splenic Gr-1
+
/CD11b
+ 
cells was assessed [6]. Gemcitabine significantly 
reduced the number of splenic MDSCs at 48 hours. This effect was specific: the numbers 
of CD4+, CD8+ and B cells were not affected. This quantitative effect was functionally 
important. When splenocytes from animals bearing large tumors were added to a mixture 
of tumour cells and CTLs in a modified Winn assay the growth inhibitory effects of the 
CTLs was lost. The addition of an equal number of splenocytes from tumour bearing 
animals treated 48 hours earlier with Gemcitabine had no such effect and the added CTLs 
maintained their suppressive activity on tumour growth. Vincent and colleagues 
confirmed this effect: 5 days following the administration of Gemcitabine there was 
significant reduction in the percentage of CD11b+ MDSCs in the spleens and tumour 
beds of tumour-bearing mice [7]. Whilst Cyclophosphamide, Doxorubicin, Oxaliplatin 
and Paclitaxel had no such effect, 5-FU also significantly reduced the percentage of 
MDSCs and to a greater degree than Gemcitabine. Again this cytoreductive effect was 
MDSC-specific. The tumour growth suppressive effects of Gemcitabine and 5-FU both 
depended on the presence of T cells and the implication from this work was that the 
chemotherapy effect on MDSCs allowed the restoration of T-cell dependent anti-tumour 
responses. 
These pre-clinical data raise the critical question as to whether chemotherapy, and in 
particular Gemcitabine and 5-FU, also results in a reduction in MDSCs in patients? We 
are aware of two clinical studies which address the effects of chemotherapy on MDSC 
numbers [8, 9]. In the first where the chemotherapy was not specified, MDSC numbers 
tracked with tumor volume in 6 patients, with numbers falling with response and 
increasing with progression. Similarly, in 25 patients with advanced colorectal cancer, 
MDSCs were significantly higher (and increased from baseline) in patients with 
progressive disease compared with those with a response to chemotherapy. Again, the 
regimen was not specified. These studies suggested that any effects on MDSCs from 
chemotherapy were likely to be related to changes in tumour volume rather than specific 
effects of chemotherapy on MDSCs per se. 
We have recently demonstrated significant elevations of MDSCs in patients with 
pancreatic cancer, and in multivariate analysis MDSC levels were shown to be an 
independent prognostic factor for survival [10]. We here prospectively analyze the effect 
of the administration of the combination of Gemcitabine and Capecitabine, a 5-FU pro-
drug, on MDSC levels in pancreatic cancer to try to answer two questions. 
1. Does the combination of gemcitabine and capecitabine, the only two chemotherapy 
agents which pre-clinically have been shown to reduce MDSC levels, have an effect on 
MDSC levels in patients with cancer, and if so does this effect appear to be independent 
of tumour response?                                                                               
2. Does any quantitative effect of gemcitabine and capecitabine on MDSCs have any 
impact at a functional level?  
Pre-clinical data demonstrates that the reduction of MDSCs enhances the efficacy of 
cancer immunotherapy [11]. Furthermore, pre-vaccination levels of MDSCs appear to 
have a significant impact on the immunogenicity of cancer vaccines in humans [12]. 
Thus, we examined the relation between changes in MDSC level and the development of 
an immune response to a cancer vaccine (GV1001) administered concomitantly with 
gemcitabine and capecitabine. GV1001 is a promiscuous class II peptide vaccine against 
human telomerase. In the phase I/II study of GV1001 in pancreatic cancer using the doses 
utilized in the current study the overall immune response to vaccine alone (proliferation 
positive and/or DTH positive) was 75% [13]. 
We demonstrate firstly that there does not appear to be a consistent effect of gemcitabine 
and capecitabine on MDSC levels independent of the effect of treatment on tumour bulk. 
Secondly, a high pre-vaccine MDSC level does not preclude an immune response to a 
cancer vaccine. However, in patients with high baseline MDSC levels who mount an 
immune response to a cancer vaccine delivered concomitantly with chemotherapy, there 
is generally a fall in MDSC levels but again this fall appears to be mainly as a result of 
disease stabilization or response secondary to chemotherapy. 
 
 
 
 
 
 
 
 
 
 
METHODS 
Patients 
20-30 mL of venous blood was collected from pancreatic cancer patients (n=40) 
participating in the TeloVac study (ISRCTN 43482138) and age/sex matched normal 
healthy controls (n=24). Age and sex matched healthy controls were recruited from 
surgical minor operation clinics at the Royal Surrey County Hospital, UK. The final 
results of TeloVac will be reported separately: the patients described herein represent a 
small sample of patients randomized and for whom suitable samples were available for 
sequential MDSC analysis. No subject had a history of autoimmune disease or of recent 
steroid therapy and no control donor had a prior history of cancer. All subjects provided 
written informed consent approved by the local human investigators committee. All 
patients were treated with combination gemcitabine and capecitabine chemotherapy: 
gemcitabine was given intravenously at 1,000 mg/m
2
 weekly × 3 every 4 weeks together 
with capecitabine administered orally at 1,660 mg/m
2
/d (830 mg/m
2
 twice daily) for 3 
weeks followed by 1 week's rest. 19 patients received combination chemotherapy alone. 
21 patients received the class II hTERT vaccine GV1001 concurrently with the same 
chemotherapy, given according at the previously published dose and schedule [13]. 
Peripheral blood samples were taken prior to and following chemotherapy. For patients 
receiving gemcitabine and capecitabine alone blood was drawn after seven weeks of 
treatment, one week following the fifth gemcitabine infusion, immediately prior to the 
sixth gemcitabine infusion and whilst the patient was taking capecitabine. For patients 
receiving gemcitabine and capecitabine concomitantly with GV1001, blood was drawn 
after 10 weeks of treatment to co-incide with an immunomonitoring time-point, one week 
after the seventh gemcitabine infusion immediately prior to the eighth gemcitabine 
infusion and whilst the patient was taking capecitabine. Blood was drawn into li-heparin 
tubes (BD Biosciences, Europe) or CPT tubes for shipment to the biomarker repository. 
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Hypaque 
gradients. PBMC were counted, frozen at -80°C and stored in liquid N2 for subsequent 
batch-analysis. 
Immunophenotypic analysis of cells 
PBMC were recovered and washed in 0.15M phosphate buffered saline, Dulbecco’s A 
(Oxoid, UK). Cells were aliquoted for MDSC analysis. The LIVE/DEAD Cell Stain Kit 
(Invitrogen, UK) was used to differentiate viable and dead cells. After washing in binding 
buffer (BD Biosciences, Europe) the following anti-human monoclonal antibodies were 
used for flow cytometry: anti-HLA-DR-APC-Cy7, anti-Lin1(CD3,14,16,19,20,56)-FITC 
and anti-CD11b-PECy7 (BD Biosciences, Europe). Following immunostaining cells were 
washed in binding buffer and analysed using a MACSQuant flow cytometer with 
MACSQuantify software (Miltenyi Biotec). 
Delayed-type hypersensitivity (DTH) skin tests 
GV1001 (100µg) was administered intradermally in the lower abdomen, contralaterally 
to the vaccination site.  Patients were asked to record the size of the DTH reaction 48 
hours after administration and report to the clinician. A positive DTH reaction was 
defined as erythema and induration with an average diameter of 5mm. 
In vitro proliferation assays  
Thawed PBMCs were seeded in 48 well plates (ThermoFisher Scientific, USA) at 2 x 10
6
 
cells/well in X-VIVO 15 (Lonza, UK) with 10% pooled human serum (Innovative 
Research, USA) and 20ug/ml GV1001 peptide. Following 3 days of culture, 10units/ml 
IL-2 (Peprotech, UK) was added to the media. On day 11, the GV1001 enriched cells 
were harvested and plated at 1 x 10
5
 cells/well (50µl) in a round bottom 96 well plate. To 
the pre-stimulated cells, irradiated (45Gy) autologous PBMCs (1 x 10
5
 cells/well 50µl) 
were added to act as antigen presenting cells (APCs). GV1001 specific proliferation was 
tested for by the addition of 100µl of either control media, GV1001 (20µg/ml) or positive 
control PHA (5µg/ml). After incubation for a further 2 days, 1µCi/well of 
3
H-thymidine 
was added for 16 hours before counting. A positive proliferative response to GV1001 was 
defined as a stimulation index (SI) above 1.8 with a significant difference in counts per 
minute from four replicates.          
 
Cytokine Analysis 
Cytokine levels were assayed on patient serum collected at the same time as PBMCs 
using the Bio Rad Bio Plex 27 Pro Cytokine, Chemokine and Growth Factor Assay (Bio 
Rad Laboratories, USA) using the Bio Rad Bio Plex Instrument following manufacturer’s 
instructions.     
Tumor Burden Assessment 
Independent assessment of tumor burden pre- and post-chemotherapy was performed by 
a radiologist blinded to MDSC results, using RECIST v1.1 criteria for measurement of 
evaluable lesions on CT imaging [14]. The sum of the long axis measurement of tumor 
lesions and short axis measurement of pathological lymph nodes was used to measure 
tumor burden in millimeters. 
Statistical Analysis 
Median levels of Lin-DR-CD11b+ cells were compared in pancreatic cancer patients 
versus controls using an unpaired t test with Welch’s correction. The correlation between 
baseline MDSC and cytokine was analysed with Spearmans Rank test and the non-
parametric Mann-Whitney test was used to identify significant differences in cytokines 
with dichotomised at median MDSC levels. Paired Wilcoxon test was used to compare 
pre and post chemotherapy cytokine levels. 
 
 
 
 
 
 
RESULTS 
Levels of pro-inflammatory cytokines do not correlate with baseline levels of Lin-DR-
CD11b+ cells in pancreatic cancer patients 
Cryopreserved PBMCs from 40 patients with advanced pancreatic cancer treated with 
gemcitabine and capecitabine chemotherapy were analysed. 21 of the patients received 
concomitant therapy with the telomerase vaccine GV1001. Their baseline pre-treatment 
values are included in the calculation of the pre-treatment medians and the correlations of 
baseline levels of pro-inflammatory cytokines with MDSC levels. In the analysis of the 
effect of gemcitabine and capecitabine on Lin-DR-CD11b+ cells only sequential samples 
in the 19 patients who received gemcitabine and capecitabine alone were analysed. This 
phenotype was used to mark MDSCs based on the recent work of Kotsakis and 
colleagues [15]. 
There was a significant increase in Lin-DR-CD11b+ cells in pancreatic cancer patients 
(n=40) compared with controls (p<0.0001). The median baseline Lin-DR-CD11b+ cells 
in patients (expressed as a % of live PBMCs) was 1.85 (range 0.62 – 8.45): 
corresponding values in 24 controls were median 0.82 (range 0.16 – 2.2). There was no 
correlation between baseline levels of pro-inflammatory cytokines and baseline MDSCs 
in the 33 pancreatic cancer patients for whom we had full cytokine data (Spearman’s 
coefficient: IL-6 = 0.153, IL-1 = 0.22, VEGF = -0.0389, TNF = 0.0587, MCP-1 = -
0.226). When MDSC levels were dichotomized at the median, there were no significant 
differences in the baseline level of these cytokines in patients with high MDSCs 
compared with those with low MDSCs (Figure 1). 
Gemcitabine and capecitabine therapy does not consistently reduce Lin-DR-CD11b+ cell 
numbers – the contribution of disease control and the degree of cancer-related 
inflammation 
In the patients receiving chemotherapy alone (n=19), gemcitabine and capecitabine 
therapy resulted in a fall in Lin-DR-CD11b+ cells in 58% of the patients. Figure 2 shows 
the percentage change in MDSCs colour coded for response (red for progressive disease, 
green for stable disease and violet for partial response) from the greatest increase to the 
greatest decrease during treatment with gemcitabine and capecitabine. In the 7 patients 
with progressive disease (PD) the Lin-DR-CD11b+ level went up in 5 and down in 2 
(range -60% to +662%). In the 10 patients with stable disease (SD) Lin-DR-CD11b+ 
levels increased in 6 and fell in 4 (range -68% to +604%). Both patients achieving a 
partial response had falls in the Lin-DR-CD11b+ %. We obtained accurate tumour 
measurements and in 8/10 of the patients with stable disease there was no significant 
increase or decrease in the sum of the longest diameters. In these patients where the 
relative contribution of a change in Lin-DR-CD11b+ % secondary to any significant 
change in tumour bulk was minimal, Lin-DR-CD11b+ % went up in 5 patients and down 
in 3. These data suggest that there is no consistent reduction in Lin-DR-CD11b+ % 
secondary to gemcitabine and capecitabine chemotherapy per se. Changes in Lin-DR-
CD11b+ % had a tendency to track relatively closely with tumour response. This is well 
demonstrated in the patients with baseline Lin-DR-CD11b+ greater than the median, the 
group where a fall in MDSCs would be most likely to be of the greatest immunological 
benefit (Table 1). In these patients the Lin-DR-CD11b+ % increased in 6 (3 with 
progressive disease and 3 with 0% tumour volume change) and in 3 it fell (1 of these 
patients obtaining a partial response and the other an 11% reduction in tumour volume). 
In only 3 of these patients was the Lin-DR-CD11b+ % less than the baseline median 
following gemcitabine and capecitabine therapy. 
Given the lack of a strict association of MDSC level changes with objective response to 
therapy we next analysed whether the changes in MDSC level tracked with changes in 
the degree of cancer-related inflammation using as a surrogate changes in IL-6 and other 
inflammatory cytokines during treatment. IL-6 levels went up in 7/19 patients during 
gemcitabine and capecitabine treatment: 4 of these patients had progressive disease. The 
other 3 had stable disease and in these 3 patients MDSC% increased: in 2 of these MDSC 
levels above median at baseline increased even further. Table 2 shows the changes in 
MDSC% against the changes in inflammatory cytokines during chemotherapy in the 
10/19 patients with stable disease. In the four patients in whom there was a fall in 
MDSC%, IL-6 fell in all 4 and in one of these patients (patient 7) a fall in IL-6 level from 
152.72pg/ml to 8.66pg/ml over 7 weeks of chemotherapy was associated with a fall in 
MDSC% from 2.54 to 1.59. In the six patients with stable disease in whom the MDSC% 
increased, in 3 the baseline MDSC level was below the median and remained so 
following chemotherapy. In two patients where an above median baseline MDSC level 
continued to rise on treatment there was a significant increase in IL-6 (patients 1 and 3 – 
VEGF levels also increased from 37.59pg/ml to 70.69pg/ml in patient 3, the only patient 
without progressive disease to show such an increase). In the remaining patient a 9% 
increase in MDSC level was associated with a 17% decrease in IL-6 level. 
High baseline MDSC levels do not preclude an immune response to a cancer vaccine 
administered concomitantly with gemcitabine and capecitabine 
As cryopreserved PBMCs were used no functional in vitro assays were performed [13]. 
As an alternative we analysed the development of an immune response to GV1001 in the 
21 patients receiving concomitant gemcitabine and capecitabine and vaccine (positive 
proliferation assay, and/or the development of a positive DTH, to GV1001). This was felt 
to be a clinically pertinent readout of the functional effect of any gemcitabine and 
capecitabine-mediated quantitative impact on MDSCs. Table 3 details the 9 patients in 
this cohort who developed an immune response. In 8/9 of these patients the MDSC% fell 
during chemo-immunotherapy. 6/9 had baseline Lin-DR-CD11b+ % greater than the 
patient median and in all of these the MDSC level fell. All immune responders had 
radiological disease control (either PR or SD) at the time that blood was drawn for the 
analysis of proliferation response, which coincided with the timing of the sequential 
MDSC assay. 
 
 
 
 
 
 
DISCUSSION 
This study demonstrates that there appears to be no consistent reduction in MDSC level 
in pancreatic cancer patients treated with gemcitabine and capecitabine. We analysed a 
homogeneously treated group of patients obtaining samples at the same time point in all, 
immediately prior to a gemcitabine infusion, one week following the last gemcitabine 
infusion and whilst the patient was taking daily capecitabine. This time point correlated 
with the first radiological assessment of tumour response. MDSC changes tended to track 
with tumour volume: most patients with progressive disease demonstrated an increased 
MDSC level during chemotherapy and those who obtained a partial response a decreased 
level. In patients with no significant change in tumour volume during therapy, 
gemcitabine and capecitabine did not consistently reduce MDSC levels as would be 
expected if the chemotherapy reduced MDSC levels independently of response, through a 
direct effect on MDSCs: MDSC level was just as likely to go up as to go down. Suzuki 
and colleagues demonstrated that a single dose of Gemcitabine significantly reduced the 
number of Gr-1+/CD11b+ cells in the spleens of mice harboring a variety of different 
tumors, with no effect on the number of CD4+, CD8+ or B cells [6]. Vincent and 
colleagues demonstrated that 5-FU triggered the dose-dependent apoptosis of MDSCs: 
thymidylate synthase levels in MDSCs were lower than in splenocytes or tumor cells [7]. 
In spite of these pre-clinical data we cannot recommend the use of gemcitabine and 
fluropyrimidine treatment in cancer patients specifically with the expectation that this 
will result in a reduction of MDSC level. Any decrease is likely to reflect predominantly 
the effect of the resultant disease control, although even in patients with no change at all 
in disease volume the MDSC level may actually go up. These data support previously 
published observations [8,9] but are important because they are from patients 
homogeneously treated with a combination of the only two chemotherapy drugs which 
pre-clinically have been shown to reduce MDSC levels directly. 
We hypothesized that longitudinal changes in MDSCs levels during gemcitabine and 
capecitabine chemotherapy might in part be related to temporal changes in the degree of 
inflammation within tumours.  A reduction in tumoural inflammation might be more 
pronounced where chemotherapy was slowing rapid tumour growth which would account 
for the modest tracking of MDSC levels with tumour response, but the degree of 
inflammation in any tumour is likely to be somewhat independent of size and growth 
dynamics and this might account for the lack of a strict association between objective 
response to chemotherapy and the trajectory of MDSC levels. This might also explain the 
differential effects on MDSC levels in patients with stable disease. We used sequential 
changes in IL-6 and other inflammatory cytokines as a surrogate for the status of cancer-
related inflammation and correlated changes in MDSC levels with changes in the levels 
of IL-6 during treatment with gemcitabine and capecitabine. We demonstrated that in 
patients with stable disease the direction of MDSC change tracked well with the direction 
of IL-6 change. These data support a model whereby significant increases in tumour 
burden during chemotherapy are likely to be associated with MDSC increases and 
significant decreases in tumour burden with decreased MDSC level whilst in those with 
little change in tumour bulk the direction of MDSC change will be determined by the 
longitudinal change in the degree of cancer-related inflammation. Continued significant 
tumoural inflammation, in spite of stabilization of tumour volume, is likely to support the 
continued production of MDSCs: reduced inflammation concomitant with disease 
stabilization is likely to limit MDSC accumulation. These two factors appear to override 
any specific quantitative effect of gemcitabine and capecitabine chemotherapy per se on 
MDSC levels. 
Given the above we were initially surprised to see no association between baseline levels 
of pro-inflammatory cytokines and baseline MDSCs. Using a 4T1 mammary carcinoma 
model Bunt and colleagues demonstrated significant elevations of the pro-inflammatory 
cytokines IL-6, MCP-1, TGFβ and IL1β in tumour tissue showing that tumour growth is 
associated with an inflammatory milieu [16]. Intratumoral inflammatory cytokine levels 
were significantly reduced and accumulation of CD11b+Gr1+ MDSCs in the blood was 
delayed in IL-1R
-/- 
mice.  Overexpression of IL-6 in 4T1 cells compensated for the loss of 
IL-1R with no delay in MDSC accumulation. However, it is important to note that the 
delay in accumulation of MDSCs in the IL-1R-/- mice was short-lived and by day 26 
from inoculation MDSC levels were at the same high level as in BALBc mice. This could 
explain a lack of correlation between baseline IL-6 (and other inflammatory cytokines 
including IL1β) and MDSC levels at a time when the cancer is already well established. 
GM-CSF appears to have more profound effects on MDSC biology than Il-1 and IL-6 in 
the 4T1 model [17], and this is supported by data demonstrating the critical role of GM-
CSF in the induction of human CD33+ MDSCs from normal PBMCs [18]. GM-CSF 
plays a key role in the generation of MDSCs in KPC mice where oncogenic KRAS and 
mutant p53 is targeted to the pancreas [19]. Levels of IL-6 were generally low in the KPC 
cell lines and tended to be higher in the normal ductal cells.  GM-CSF drove GR-1+ 
CD11b+ cell generation whereas IL-6 was minimally effective: neutralization of GM-
CSF completely abrogated MDSC generation from c-kit+ precursors by conditioned 
media whereas anti-IL-6 had no effect. 19/20 human pancreatic ductal adenocarcinoma 
samples expressed GM-CSF by immunocytochemistry. Serum GM-CSF levels were 
generally below the level of detection with our assay precluding any useful correlation of 
GM-CSF levels and MDSC dynamics. Very low levels of GM-CSF relative to other 
haematopoietic cytokines in patients with pancreatic cancer have been previously 
reported [20]. 
One limitation of this study is the number of patient samples analysed. However, it is 
well appreciated that obtaining sequential PBMC samples for MDSC evaluation is 
difficult.  As we point out in the introduction, we are aware of only two studies that 
address the effect of chemotherapy on sequential MDSCs; one analyses only six patients 
and in the second analysing 25 patients, the regimen was not specified [8, 9].  
A further limitation of this study is that it utilized cryopreserved cells.  This reflects the 
reality of obtaining PBMC samples from multiple centres in the context of a clinical trial 
and the advantages of batch testing stored samples. An important recent study 
demonstrated that cryopreservation led to a significant reduction in the percentage of DR-
Lin-CD33+ and DR-Lin-CD15+ cells compared to fresh cells, whereas the percentages of 
the monocytic cell populations, DR-Lin-CD11b+ and DR-/low CD14+ cells were not 
significantly affected by cryopreservation [15]. Hence, we restricted our quantitative 
analysis to the Lin-DR-CD11b+ monocytic MDSC subset, which is little effected in 
terms of recovery, viability and phenotype by cryopreservation. It is worth noting that the 
medians and ranges which we derived in the current study are very similar to those in our 
previous work where we phenotyped MDSCs as Lin-/low DR- CD11b+ CD33+ [10]. 
Kotsakis and colleagues also demonstrated that freezing had a profound effect on the 
function of recovered MDSCs [13]. Freezing and re-thawing abolished the inhibitory 
effects of MDSCs on the proliferation of stimulated autologous CD4+ cells, MDSC 
arginase positivity and PMA/ionomycin- stimulated ROS production by MDSCs. Thus, 
we did not perform any functional assays on our cryopreserved cells as this would not 
have provided any useful additional information. Instead, we sought to understand the 
functional effect of any gemcitabine and capecitabine-mediated quantitative effects on 
MDSCs by correlating the effects of chemotherapy on MDSC levels with the 
development of an immune response to the GV1001 vaccine. 
The MDSC level fell in 8 of the 9 patients who developed an immune response to 
GV1001 administered concomitantly with gemcitabine and capecitabine. In 6 of these 
patients the initial pre-vaccination MDSC level was above the median for the cancer 
patient cohort. A direct causal relationship cannot be claimed on the basis of these data - 
that disease control secondary to chemotherapy reduces circulating MDSC levels and this 
permits the development of an immune response to a concomitantly administered cancer 
vaccine. However, high pre-vaccination MDSC levels are clearly not an absolute bar to 
the development of immunity to a tumour associated antigen. It is reasonable to 
hypothesise that this is more likely to occur with any concomitantly administered 
treatment which checks the progress of increasing immunosuppression which will occur 
with increasing volumes of disease and/or increasing levels of cancer-related 
inflammation either in untreated patients or in those who fail to gain control of their 
disease on therapy. 
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Figure Legends 
Fig. 1 No significant differences in the level of pro-inflammatory cytokines in patients 
with high MDSCs compared with those with low MDSCs 
Peripheral blood mononuclear cells from 33 pancreatic cancer patients obtained pre- 
treatment (at baseline) were immunostained for HLA-DR-APC-Cy7, 
Lin1(CD3,14,16,19,20,56)-FITC and CD11b-PECy7 and with ViViD to discriminate live 
and dead cells. Following immunostaining cells were analysed using a MACSQuant flow 
cytometer with MACSQuantify software. In addition serum cytokines TNFα, MCP-1, IL-
1b, IL-6 and VEGF were determined using the Bio Rad Bio Plex 27 Pro Cytokine, 
Chemokine and Growth Factor assay using the Bio Rad Bio Plex Instrument. Baseline 
MDSCs dichotomized at median (1.85) plotted with baseline IL-6, IL-1b, VEGF, TNFα, 
and MCP-1 (pg/ml). P value generated for Mann-Whitney test shows no significant 
differences. 
Fig. 2 Gemcitabine and Capecitabine therapy does not consistently reduce Lin-DR-
CD11b+ MDSCs 
In patients receiving chemotherapy alone (n=19) PBMCs were obtained pre and post-
treatment and immunostained for HLA-DR-APC-Cy7, Lin1(CD3,14,16,19,20,56)-FITC 
and CD11b-PECy7 as well as ViViD to discriminate live and dead cells. Following 
immunostaining cells were analysed using a MACSQuant flow cytometer with 
MACSQuantify software. The graph depicts the percentage change in Lin-DR-CD11b+ 
MDSCs from baseline in patients during treatment with Gemcitabine and Capecitabine. 
Red denotes patients with progressive disease on treatment, green stable disease and 
violet partial response by RECISTv1.1. 
Table 1. Changes in Lin-DR-CD11b+ cells during chemotherapy in patients with 
baseline values > median. 
Cryopreserved PBMCs obtained from patients with advanced pancreatic cancer before 
(baseline) and after treatment with gemcitabine and capecitabine chemotherapy were 
immunostained for HLA-DR-APC-Cy7, Lin1(CD3,14,16,19,20,56)-FITC and CD11b-
PECy7 and ViViD to discriminate live and dead cells. Following immunostaining cells 
were analysed using a MACSQuant flow cytometer with MACSQuantify software. 
Numbers represent % change in the Lin-DR-CD11b+ cells only in those patients with 
baseline Lin-DR-CD11b+ greater than the median. There was no consistent reduction in 
Lin-DR-CD11b+ % secondary to gemcitabine and capecitabine chemotherapy. SD = 
stable disease and PR = partial response and PD = progressive disease 
Table 2. Changes in MDSC% during gemcitabine and capecitabine chemotherapy 
correlated with changes in serum TNFα, MCP-1, IL-1b, IL-6 and VEGF in patients 
with stable disease on therapy.  
PBMC from ten patients with stable disease during gemcitabine and capecitabine 
treatment were analysed both pre and post treatment by flow cytometry for changes in 
Lin-DR-CD11b+ cells and changes in serum cytokines TNFα, MCP-1, IL-1b, IL-6 and 
VEGF by the Bio Rad Bio Plex 27 Pro Cytokine, Chemokine and Growth Factor assay. 
Table 3. Trajectory of Lin-DR-CD11b+ percentage in immune responders in 
patients receiving concomitant GV1001 and gemcitabine/capecitabine 
chemotherapy. 
PBMC from nine patients who developed an immune response (positive proliferation 
assay, and/or the development of a positive DTH) to the vaccine GV1001 whilst also 
receiving concomitant gemcitabine and capecitabine were immunostained for Lin-DR-
CD11b+ MDSCs and analysed by flow cytometry both at baseline and post therapy.  
DTH = delayed type hypersensitivity testing to GV1001, NR = not reported, ORR = 
objective radiological response, SD = stable disease and PR = partial response. 
 
 
 
 
